CMRA - Comera Life Sciences Holdings, Inc.
| Previous close | 0.4898 |
| Open | 0.4500 |
| Bid | 0.4050 x 1100 |
| Ask | 0.4314 x 1100 |
| Day's range | 0.4049 - 0.5131 |
| 52-week range | 0.3700 - 5.7000 |
| Volume | |
| Avg. volume | 15,593 |
| Market cap | 9.622M |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights
– Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera’s pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera’s patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life scie
- GlobeNewswire
Comera Life Sciences to Participate in Four Upcoming Conferences
WOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced that its scientists and executives will participate in four upcoming scientific and industry conferences. “We look forward to sharing more about our proprietary formulation platform and partnering opportunities at thes
- GlobeNewswire
Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology
– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™ platform – – Patent granted in South Korea and Notice of Allowance received for patent application in Japan for excipients in SQore™ platform – – Continued expansion of Comera’s patent portfolio further strengthens its in-house intellectual property and may create value for potential partners – WOBURN, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences H
- GlobeNewswire
Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) – – Joined the Subcutaneous Drug Development & Delivery Consortium (SC Consortium) to advance the science, technology, and best practices for subcutaneous (SQ) drug development and delivery – WOBURN, Mass., March 16, 2023 (GLO
- GlobeNewswire
Comera Life Sciences to Present at 22nd Annual PepTalk Conference
WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced it will present at the 22nd Annual PepTalk Conference, in San Diego on Wednesday, Jan. 18, 2023 at 5:15 p.m. PT. The conference will run from Monday, Jan. 16 through Friday, Jan. 20. Subhashchandra Naik, Ph.D., Senior R
- GlobeNewswire
Comera Life Sciences to Present at Upcoming Biotech Showcase Investor Conference
WOBURN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced that the company will present at the upcoming Biotech Showcase Conference on Tuesday, January 10, 2023 at 9:00 AM PT in San Francisco, CA. The Company will also host one-on-one meetings with investors from Monday, January 9 through W
- GlobeNewswire
Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that it has completed a private placement to existing stockholders, of 2,406,242 units, at a purchase price of $1.48 per unit, with each unit consisting of one share of the Company’s common stock and one five-year warrant to purchase two shar
- GlobeNewswire
Comera Life Sciences to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it will be participating in the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1, 2022 at the New York Athletic Club in New York. Interested parties can access a copy of Comera’s current
- GlobeNewswire
Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) – WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety,
- GlobeNewswire
Comera Life Sciences Appoints Janice Marie McCourt as Chief Business Officer
WOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced the appointment of Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic trans
- GlobeNewswire
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study, the preclinical results showed that Comera’s caffeine-based SQore™ excipient did not result in local or systemic toxicity and had no impact on an
- GlobeNewswire
Comera Life Sciences Expands Woburn Operations
Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square fe
- GlobeNewswire
Comera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business Solutions
WOBURN, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced entry into a purchase agreement with Arena Business Solutions Global SPC II, Ltd. (“Arena”) for up to $15 million of the Company’s common stock, with an option to increase by an additional $15 million to $30 million. “T
- GlobeNewswire
Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit
WOBURN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced that topline data from its preclinical SEQURUS-2 study will be presented at the 14th Annual Bioprocessing Summit, which will be held in Boston from August 15 – 18, 2022. The Company will also host a booth (#419) in the
- GlobeNewswire
Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022
WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provided a business update and reported financial results for the quarter ended June 30, 2022. “This has been a historic year for Comera, as we have transitioned into a public company, completed a significant collaboration with Intas, and made importan
- Business Wire
Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform
WOBURN, Mass., June 22, 2022--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the ‘857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore™ platform as viscosity-lowering agents to significantly optimize filtration efficiency of prote
- Business Wire
Comera Life Sciences Appoints Michael Campbell as Executive Vice President and Chief Financial Officer
WOBURN, Mass., June 16, 2022--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of Michael Campbell as Executive Vice President and Chief Financial Officer. He had served as interim Chief Financial Officer since April 13, 2022 and will continue to oversee Comera’s finance operations, including accounting and reporting, corp
